

## American Diabetes Association's 81st Scientific Sessions overview, STENO DIABETES CENTER COPENHAGEN

(all sessions will take place in U.S. Eastern Time, i.e. you must add 6 hrs. to the time in the program if viewing in Denmark)

Time	No	Title	Authors	Category
<b>Friday Jun 25</b>				
<b>21:30-22:00 (3:30-4:00 p.m.)</b>	Invited	How Will New Clinical Trials Affect Evidence-Based Care for People with Diabetes and Kidney Disease?	<b>Peter Rossing</b>	Acute and Chronic Complications; Evidence-Based Guidelines for Diabetes and Chronic Kidney Disease
<b>23:00 (5:00 p.m.)</b>	10-OR	In Women with Prior Gestational Diabetes Mellitus, the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Improves Glucose Tolerance Irrespective of Body Weight Loss after Five Years of Treatment, but Effects Are Lost after Wash-Out	<b>Emilie S. Andersen</b> , Signe Foghsgaard, Louise Vedtofte, Marie H. Pedersen, Julie Forman, Elisabeth R. Mathiesen, Jens Svare, Jens J. Holst, Tine D. Clausen, Peter Damm, Filip K. Knop, Tina Vilsbøll	Clinical Diabetes/Therapeutics; Prevention of Diabetes and Diabetes Complications
<b>Saturday Jun 26</b>				
<b>14:15 (8:15 a.m.)</b>	45-OR	Hypoglycemia, Glycemic Variability and Risk of Cardiac Arrhythmias Using a Long-Term Monitoring Approach in Insulin-Treated Patients with Type 2 Diabetes	<b>Andreas Andersen</b> , Jonatan I. Bagger, Samuel K. Sørensen, Maria P. A. Baldassarre, Ulrik Pedersen-Bjergaard, Julie Forman, Gunnar Gislason, Tommi B. Lindhardt, Filip K. Knop, Tina Vilsbøll	Acute and Chronic Complications; Hypoglycemia, Heart, and Mind
<b>14:45 (8:45 a.m.)</b>	47-OR	Acute Fluctuations in Plasma Glucose Affect Echocardiographic-Derived Measures of Systolic Function in Patients with Type 1 Diabetes	<b>Christine R. Andreasen</b> , Andreas Andersen, Per G. Hagelqvist, Kirsten U. Abelin, Julius V. Lauritsen, Peter G. Jorgensen, Susanne Engberg, Jens J. Holst, Ulrik Pedersen-Bjergaard, Filip K. Knop, Tina Vilsbøll	Acute and Chronic Complications; Hypoglycemia, Heart, and Mind
<b>22:30 (4:30 a.m.)</b>	103-OR	The Glucagon-Like Peptide-1 Analog, Liraglutide Is a Safe and Effective Treatment of Bile Acid Malabsorption: A Proof of Concept Study	<b>Martin L. Kårhus</b> , Andreas Brønden, Julie Forman, Anne Haaber, Ebbe Langholz, Tina Vilsbøll, David P. Sonne, Filip K. Knop	Clinical Diabetes/Therapeutics; Incretin-Based Therapies
<b>23:45 (5:45 p.m.)</b>	107-OR	Six-Day Subcutaneous GIP Infusion Increases Circulating Free Fatty Acids without Altering the Adipose Tissue Transcriptome, Adipocyte GIP Receptor Levels, or Circulating Inflammation Markers in Patients with Type 1 Diabetes	<b>Sebastian M. Nguyen Heimbürger</b> , Bjørn Hoe, Chris N. Nielsen, Bolette Hartmann, Jens J. Holst, Flemming Dela, Anne J. Overgaard, Joachim Størling, Tina Vilsbøll, Thomas F. Dejgaard, Charles Pyke, Mikkel B. Christensen, Filip K. Knop	Clinical Diabetes/Therapeutics; Incretin-Based Therapies
<b>Sunday Jun 27</b>				
<b>14:00 (8:00 a.m.)</b>	131-OR	ADA Presidents' Select Abstract Presentation: Effect of Insulin Degludec vs. Insulin Glargine U100 on Occurrence of Nocturnal Hypoglycemia Assessed by	Julie M. Brøsen, Rikke Agesen, Peter L. Kristensen, Sr., Amra Ciric Alibegovic, Henrik U. Andersen, Peter Gustenhoff, Christoffer	Acute and Chronic Complications;

		Nocturnal Plasma Glucose Profiles in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia	Hedetoft, Tonny Jensen, Sr., Claus B. Juhl, Susanne Lerche, <b>Kirsten Nørgaard</b>	Hypoglycemia by Day and by Night—Mechanisms and Management
<b>14:45 (8:45 a.m.)</b>	150-OR	Intermittently Scanned Continuous Glucose Monitoring and Automated Bolus Calculation in Type 1 Diabetes Treated with Multiple Daily Insulin Injections: A Randomized Controlled Trial	<b>Anna L. Secher</b> , Ulrik Pedersen-Bjergaard, Ole L. Svendsen, Birthe Gade-Rasmussen, Thomas P. Almdal, Linda H. Raimond, Dorte Vistisen, Kirsten Nørgaard	Clinical Diabetes/Therapeutics; Glucose Monitoring and Sensing
<b>15:00-15:30 (9:00 a.m.)</b>	Invited	Insulin and GLP-1Ras	<b>Tina Vilsbøll</b>	Clinical Diabetes/Therapeutics; Matchmaker, Matchmaker, Make Me a Match—Selecting Glucose-Lowering Combinations for Type 2 Diabetes Mellitus
<b>21:45 (3:45 p.m.)</b>	Invited	Going High Tech for Physical Activity—Using Insulin Pumps, Continuous Glucose Monitors, and Bolus Calculators	<b>Ajenthem G. Ranjan</b>	Behavioral Medicine, Clinical Nutrition, Education, and Exercise; Aiming for Balance—Type 1 Diabetes and Exercise Management Perfected
<b>22:00 (4:00 p.m.)</b>	189-OR	FIDELIO-DKD Study: Analysis of Effects of Finerenone by Baseline A1C	<b>Peter Rossing</b> , Ellen Burgess, Rajiv Agarwal, Stefan Anker, Gerasimos Filippatos, Bertram Pitt, Luis M. Ruilope, Pieter Gillard, Amer Joseph, Meike Daniela Brinker, Charlie Scott, George Bakris	Acute and Chronic Complications; Highlights in Diabetic Kidney Disease Research—Basic, Clinical, and Translational Science
<b>23:15 (5:15 p.m.)</b>	215-OR	Performance of a Dual Hormone Closed-Loop System vs. an Insulin-Only Closed-Loop System during Challenging Inpatient Conditions: A Single-Blinded Randomized Controlled Crossover Trial	<b>Ajenthem G. Ranjan</b> , Dimitri Boiroux, Christian Laugesen, Signe Schmidt, Asbjørn T. Reenberg, John B. Jørgensen, Kirsten Nørgaard	Clinical Diabetes/Therapeutics; Insulin Delivery Systems
<b>Monday Jun 28</b>				
<b>14:15 (8:15 a.m.)</b>	258-OR	The Glucagonotropic Effect of GLP-2 during Hypoglycemia, Euglycemia, and Hyperglycemia in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study	<b>Nina L. Hansen</b> , Tore Magnussen, Jens J. Holst, Bolette Hartmann, Mikkel B. Christensen, Asger Lund, Filip K. Knop	Integrated Physiology/Obesity; Glucagon, Incretins, and Other Hormones in Humans
<b>14:45 (8:45 a.m.)</b>	237-OR	Low-Dose Dasiglucagon vs. Oral Carbohydrates for Prevention of Insulin-Induced Hypoglycemia in People with Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study	<b>Christian Laugesen</b> , Ajenthem Ranjan, Signe Schmidt, Kirsten Nørgaard	Clinical Diabetes/Therapeutics; Novel Therapeutic Agents and Approaches

<b>15:00 (9:00 a.m.)</b>	261-OR	Transcriptional Profiling of the Intestinal Serotonin System in Individuals with Type 2 Diabetes and Healthy Individuals	<b>Christian Legart</b> , Christoffer A. Hagemann, Anne Marie Ellegaard, Damien Keating, Tina Jorsal, Filip K. Knop	Integrated Physiology/Obesity; Glucagon, Incretins, and Other Hormones in Humans
<b>15:15 (9:15 a.m.)</b>	Invited	Diabetic Ketoacidosis	<b>Kirsten Nørgaard</b>	Clinical Diabetes/Therapeutics; Management of Type 1 Diabetes in Adults—2021 Draft ADA/EASD Consensus Report
<b>22:30 (4:30 p.m.)</b>	317-OR	Efficacy and Safety of Dapagliflozin by Glycemic Status in the DAPA-CKD Trial	<b>Frederik Persson</b> , Peter Rossing, Priya Vart, Glenn M. Chertow, Fan Fan Hou, John J. McMurray, Ricardo Correa-Rotter, Harpreet S. Bajaj, Bergur Stefansson, Robert D. Toto, Anna Maria Langkilde, David C. Wheeler, Hidde L. Heerspink, DAPA-CKD Study Group	Clinical Diabetes/Therapeutics; SGLT Inhibitors
<b>22:45 (4:45 p.m.)</b>	318-OR	Dapagliflozin Acutely Improves Renal Cortical Oxygenation in Individuals with Type 1 Diabetes and Albuminuria	<b>Jens Christian Laursen</b> , Niels Søndergaard-Heinrich, Joana Mendes Lopes de Melo, Bryan Haddock, Ida Kirstine Bull Rasmussen, Farzaneh Safavimanesh, Christian Stevns Hansen, Joachim Størling, Henrik Bo Wiberg Larsson, Per-Henrik Groop, Marie Frimodt-Møller, Ulrik Bjørn Andersen, Peter Rossing	Clinical Diabetes/Therapeutics; SGLT Inhibitors
<b>POSTER PRESENTATIONS – available from Friday 17:30 (11:30 a.m.) and throughout the meeting</b>				
	355-P	Decreased BCAAs and Elevated Fatty Acids during Repeated Episodes of Hypoglycemia in Individuals with Type 1 Diabetes	<b>Rui She</b> , Naba Al-Sari, Ismo Mattila, Peter Henriksen, Anne-Sophie Sejling, Jens Pedersen, Cristina Legido-Quigley, Ulrik Pedersen-Bjergaard	Complications - Hypoglycemia
	380-P	Endothelial Glycocalyx Dimensions and Cardiovascular Risk Factors in Type 1 Diabetes	<b>Elisabeth Buur Stougaard</b> , Signe Winther, Hanan Amadid, Marie Frimodt-Moeller, Frederik Persson, Tine W. Hansen, Peter Rossing	Complications—Macrovascular—Atherosclerotic Cardiovascular Disease and Human Diabetes
	405-P	Efficacy and Safety of Finerenone in Patients with CKD and T2D by Baseline Insulin Treatment	<b>Peter Rossing</b> , Rajiv Agarwal, Stefan Anker, Gerasimos Filippatos, Bertram Pitt, Luis M. Ruilope, Richard Macisaac, Julio Wainstein, Amer Joseph, Lothar Roessig, Charlie Scott, George Bakris	Complications—Nephropathy—Clinical and Translational Research

	406-P	Efficacy and Safety of Finerenone in Patients with CKD and T2D by GLP-1RA Treatment	<b>Peter Rossing</b> , Rajiv Agarwal, Stefan Anker, Gerasimos Filippatos, Bertram Pitt, Luis M. Ruilope, Aslam Amod, Michel Marre, Amer Joseph, Andrea Z. Lage, Charlie Scott, George Bakris	Complications—Nephropathy—Clinical and Translational Research
	430-P	Urinary Proteome and Diabetic Retinopathy in the Direct-Protect 1 and 2 Trials	<b>Viktor Rotbain Curovic</b> , Pedro Magalhães, Tianlin He, Tine W. Hansen, Harald Mischak, Peter Rossing	Complications—Retinopathy
	576-P	Maintenance of Time-Restricted Eating in Daily Life to Lose Weight and Lower Risk of Type 2	<b>Natasja Bjerre</b> , Lotte Holm, Jonas S. Quist, Kristine Færch, Nana F. Hempler	Psychosocial/Behavioral Medicine
	648-P	Glucose-Dependent Insulinotropic Polypeptide (GIP) Induces Lipolysis during Stable Basal Insulin Substitution and Hyperglycemia in Men with Type 1 Diabetes	<b>Chris N. Nielsen</b> , Sebastian M. Nguyen Heimburger, Salvatore Calanna, Jens J. Holst, Tina Vilsbøll, Filip K. Knop, Mikkel B. Christensen	Clinical Therapeutics/New Technology—Incretin-Based Therapies
	675-P	Effects of Liraglutide in T1D by Baseline Anthropometrics in ADJUNCT One and Two	<b>Thomas F. Dejgaard</b> , Lars Bardtrum, Erik Christiansen, Frederik Kreiner, Sten Madsbad, Matthias G. von Herrath, Bernt Johan von Scholten, Chantal Mathieu	Clinical Therapeutics/New Technology—Incretin-Based Therapies
	770-P	The Glucose-Lowering Effect of the Bile Acid Sequestrant Sevelamer Is Not Mediated by Glucagon-Like Peptide-1	<b>Henriette H. Nerild</b> , Andreas Brønden, David P. Sonne, Jens J. Holst, Tina Vilsboll, Filip K. Knop	Clinical Therapeutics/New Technology—Other Therapeutic Agents
	802-P	Dapagliflozin improves glycolytic reserve in peripheral blood mononuclear cells in patients with type 1 diabetes	<b>Joana Melo</b> , Jens Christian Laursen, Niels S. Heinrich, Ida B. Rasmussen, Christian S. Hansen, Marie Frimodt-Moeller, Peter Rossing, Joachim Størling	Clinical Therapeutics/New Technology—SGLT Inhibitors
	968-P	Cardiovascular Risk Management in the Elderly: A Nationwide Register Study of Discontinuation Patterns Prior to Death	<b>Vanja Kosjerina</b> , Bendix Carstensen, Marit E. Jørgensen, Birgitte Brock, Hanne R. Christensen, Jørgen Rungby, Gregers S. Andersen	Epidemiology—Aging
	1054-P	Incidence of Micro- and Macrovascular Complications among Persons with Type 2 Diabetes with and without Severe Mental Illness: A Nationwide Study	<b>Stine H. Scheuer</b> , Vanja Kosjerina, Nanna Lindekilde, Frans Pouwer, Bendix Carstensen, Marit E. Jørgensen, Michael E. Benros, Gregers S. Andersen	Epidemiology—Diabetes Complications
	1179-P	Acute Physiological Effects of Gastric Aspiration for the Treatment of Obesity	<b>Ida Marie Gether</b> , Marie M. Jensen, Tina Jorsal, Christina Nexoe-Larsen, Larke S. Gasbjerg, Lars P.S. Naver, Jens J. Holst, Tina Vilsboll, Filip K. Knop	Integrated Physiology—Macronutrient Metabolism And Food Intake
	1191-P	Increased Glucagon Sensitivity in Totally Pancreatectomized Patients	<b>Iben Rix</b> , Asger Lund, Lars F. Garvey, Klara Owen, Carsten Hansen, Gerrit Van Hall, Jens J. Holst, Tina Vilsboll, Filip K. Knop	Integrated Physiology—Other Hormones

	1192-P	Robust Arginine-Stimulated Glucagon Secretion in Patients with Type 1 Diabetes Independent of Diabetes Duration, Age, HbA1c, and Beta-Cell Secretory Capacity	<b>Julie Warnoe</b> , Nicklas J. Johansen, Asger Lund, Jonatan I. Bagger, Sr., Nicolai J. Wewer Albrechtsen, Bolette Hartmann, Jens J. Holst, Tina Vilsboll, Henrik U. Andersen, Thomas F. Dejgaard, Filip K. Knop	Integrated Physiology—Other Hormones
	1215-P	Effects of Exogenous Secretin on Postprandial Plasma Glucose and Lipids and Gallbladder Motility and Hemodynamics in Man	<b>Bentzen MJ</b> , Heimbürger SMN, Hartmann B, Holst JJ, Christensen MB, Knop FK	Obesity-Human
	1224-P	Exogenous Secretin Decreases Energy Intake and Exerts a Bimodular Effect on Postprandial Brown Adipose Tissue Activation in Man	Heimbürger SMN, <b>Bentzen MJ</b> , Hartmann B, Holst JJ, Christensen MB, Knop FK	Obesity-Human
	14-LB	Finerenone in Patients with CKD and T2D by SGLT2i Treatment: An Analysis of the FIDELIO-DKD Study	<b>Peter Rossing</b> , Rajiv Agarwal, Stefan Anker, Gerasimos Filippatos, Bertram Pitt, Luis M. Ruilope, Juliana C. Chan, Adriaan Kooy, Kieran Mccafferty, Guntram Schernthaner, Christoph Wanner, Amer Joseph, Markus F. Scheerer, Charlie Scott, George Bakris	Complications—Nephropathy—Clinical and Translational Research
	85-LB	Glucose-Dependent Insulinotropic Polypeptide (GIP) Contributes Substantially to the Improved Beta-Cell Function during Sitagliptin Treatment in Persons with Type 2 Diabetes	<b>Signe Stensen</b> , Larke S. Gasbjerg, Mette M. Rosenkilde, Bolette Hartmann, Tina Vilsboll, Jens J. Holst, Mikkel B. Christensen, Filip K. Knop	Clinical Therapeutics/New Technology—Incretin-Based Therapies
	130-LB	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients with Chronic Kidney Disease	<b>Peter Rossing</b> , Priya Vart, Glenn M. Chertow, Fan Fan Hou, Niels Jongs, John J. McMurray, Ricardo Correa-Rotter, Bergur Stefansson, Robert D. Toto, Anna Maria Langkilde, David C. Wheeler, Hiddo L. Heerspink, DAPA-CKD Study Group	Clinical Therapeutics/New Technology—SGLT Inhibitors